Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1608

1.

SARC-F combined with simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease.

Hiraoka A, Nagamatsu K, Izumoto H, Yoshino T, Adachi T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K.

Hepatol Res. 2019 Dec 12. doi: 10.1111/hepr.13469. [Epub ahead of print]

PMID:
31830344
2.

Japanese government research grants for Kampo medicine: aAn overview of 10 years (1997-2017).

Hyun MK, Yoon HY, Yoshino T, Park MJ.

Integr Med Res. 2019 Dec;8(4):279-283. doi: 10.1016/j.imr.2019.11.006. Epub 2019 Nov 14.

3.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T.

ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

4.

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kitano S, Kojima T, Daiko H, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A.

Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0622-3. [Epub ahead of print]

PMID:
31761900
5.

Longitudinal Analysis of Bidirectional Relationships Between Nocturia and Depressive Symptoms: The Nagahama Study.

Funada S, Tabara Y, Negoro H, Akamatsu S, Yoshino T, Yoshimura K, Watanabe N, Furukawa T, Matsuda F, Ogawa O; Nagahama Study Group.

J Urol. 2019 Nov 21:101097JU0000000000000683. doi: 10.1097/JU.0000000000000683. [Epub ahead of print]

PMID:
31750764
6.

Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus.

Hiraoka A, Nagamatsu K, Izumoto H, Adachi T, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Suga Y, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K.

Hepatol Res. 2019 Nov 14. doi: 10.1111/hepr.13430. [Epub ahead of print]

PMID:
31729124
7.

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T.

J Clin Oncol. 2019 Nov 14:JCO1902107. doi: 10.1200/JCO.19.02107. [Epub ahead of print]

PMID:
31725351
8.

LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.

Inoue T, Kaneko T, Muramatsu S, Kimura H, Yoshino T, Goto T, Sawada A, Akamatsu S, Kobayashi T, Yamasaki T, Kaya T, Ogawa O.

Clin Genitourin Cancer. 2019 Oct 17. pii: S1558-7673(19)30315-5. doi: 10.1016/j.clgc.2019.10.011. [Epub ahead of print]

PMID:
31711843
9.

[Clinical Effect of Nivolumab on Advanced Renal Cell Carcinoma with Peritoneal Metastasis].

Hida T, Yamasaki T, Banno H, Fuchigami Y, Hattahara K, Fujiwara M, Suzuki R, Kita Y, Yoshino T, Goto T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O.

Hinyokika Kiyo. 2019 Oct;65(10):413-419. doi: 10.14989/ActaUrolJap_65_10_413. Japanese.

PMID:
31697887
10.

Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.

Demachi K, Bando H, Nomura H, Shitara K, Yoshino T, Yamaguchi M, Kawasaki T.

Jpn J Clin Oncol. 2019 Nov 6. pii: hyz157. doi: 10.1093/jjco/hyz157. [Epub ahead of print]

PMID:
31693138
11.

Hepatic transcriptional profile and tissue distribution of cytochrome P450 1-3 genes in the red-crowned crane Grus japonensis.

Kawai YK, Itou K, Yoshino T, Iima H, Matsumoto F, Kubota A.

Comp Biochem Physiol C Toxicol Pharmacol. 2019 Nov 13;228:108643. doi: 10.1016/j.cbpc.2019.108643. [Epub ahead of print]

PMID:
31669699
12.

Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review.

Makimoto G, Ohashi K, Taniguchi K, Soh J, Taniguchi A, Miyahara N, Toyooka S, Yoshino T, Maeda Y, Kiura K.

Respir Med Case Rep. 2019 Sep 24;28:100938. doi: 10.1016/j.rmcr.2019.100938. eCollection 2019.

13.

Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study.

Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, Yoshino T.

Jpn J Clin Oncol. 2019 Oct 28. pii: hyz149. doi: 10.1093/jjco/hyz149. [Epub ahead of print]

PMID:
31665356
14.

Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).

Kageyama C, Igawa T, Gion Y, Iwaki N, Tabata T, Tanaka T, Kondo E, Sakai H, Tsuneyama K, Nomoto K, Noguchi H, Yoshino T, Yokota K, Sato Y.

Pathol Int. 2019 Oct;69(10):572-579. doi: 10.1111/pin.12856.

PMID:
31631463
15.

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.

Lenz HJ, Argiles G, Yoshino T, Lonardi S, Falcone A, Limón ML, Sobrero A, Hastedt C, Peil B, Voss F, Griebsch I, Van Cutsem E.

Clin Colorectal Cancer. 2019 Dec;18(4):269-279.e5. doi: 10.1016/j.clcc.2019.08.005. Epub 2019 Sep 4.

16.

Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study.

Takahashi K, Yoshino T, Maki Y, Ishiuchi K, Namiki T, Ogawa-Ochiai K, Minamizawa K, Makino T, Nakamura T, Mimura M, Watanabe K.

Arch Toxicol. 2019 Nov;93(11):3111-3119. doi: 10.1007/s00204-019-02588-2. Epub 2019 Oct 11.

PMID:
31605160
17.

Catalytic Enantioselective Methylene C(sp3 )-H Amidation of 8-Alkylquinolines Using a Cp*RhIII /Chiral Carboxylic Acid System.

Fukagawa S, Kojima M, Yoshino T, Matsunaga S.

Angew Chem Int Ed Engl. 2019 Dec 9;58(50):18154-18158. doi: 10.1002/anie.201911268. Epub 2019 Nov 11.

PMID:
31593365
18.

Rapid discrimination of fungal species by the colony fingerprinting.

Maeda Y, Sugiyama Y, Lim TK, Harada M, Yoshino T, Matsunaga T, Tanaka T.

Biosens Bioelectron. 2019 Dec 15;146:111747. doi: 10.1016/j.bios.2019.111747. Epub 2019 Sep 30.

PMID:
31586763
19.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J.

N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30.

PMID:
31566309
20.

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Biomed Rep. 2019 Oct;11(4):171-180. doi: 10.3892/br.2019.1235. Epub 2019 Aug 21.

21.

JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.

Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1269-1277. doi: 10.1007/s00280-019-03957-5. Epub 2019 Sep 23.

22.

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.

Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T.

Cancer Sci. 2019 Nov;110(11):3565-3572. doi: 10.1111/cas.14198. Epub 2019 Oct 21.

23.

Differences in demographics and complementary and alternative medicine use between patients attending integrative kampo versus biomedical clinics in Japan.

Melby MK, Yoshino T, Tonob D, Horiba Y, Watanabe K.

Complement Ther Med. 2019 Oct;46:202-209. doi: 10.1016/j.ctim.2019.06.003. Epub 2019 Jun 4.

PMID:
31519280
24.

Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.

Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H.

Clin Cancer Res. 2019 Dec 1;25(23):7089-7097. doi: 10.1158/1078-0432.CCR-19-2004. Epub 2019 Sep 12.

PMID:
31515458
25.

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.

Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M.

JAMA Oncol. 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print]

PMID:
31513248
26.

Feasibility of flow cytometric analysis of restricted light chain in endoscopic biopsy specimens from patients with gastrointestinal tract B cell lymphoma: a pilot study.

Matsueda K, Iwamuro M, Takahashi T, Omote S, Nishida K, Tanaka T, Ennishi D, Otsuka F, Yoshino T, Okada H.

BMC Res Notes. 2019 Sep 11;12(1):571. doi: 10.1186/s13104-019-4578-4.

27.

Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.

Saijo M, Nakamura K, Ida N, Nasu A, Yoshino T, Masuyama H, Yanai H.

Am J Surg Pathol. 2019 Nov;43(11):1493-1500. doi: 10.1097/PAS.0000000000001353.

PMID:
31478942
28.

Imidate as the Intact Directing Group for the Cobalt-Catalyzed C-H Allylation.

Tanaka R, Tanimoto I, Kojima M, Yoshino T, Matsunaga S.

J Org Chem. 2019 Oct 18;84(20):13203-13210. doi: 10.1021/acs.joc.9b01972. Epub 2019 Sep 6.

PMID:
31449413
29.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI.

Clin Cancer Res. 2019 Dec 1;25(23):7035-7045. doi: 10.1158/1078-0432.CCR-19-1324. Epub 2019 Aug 4.

PMID:
31383735
30.

Site-Selective Doping and Site-Sensitive Photoluminescence of Eu3+ and Tb3+ in Perovskite-Type LaLuO3.

Ueda K, Tanaka S, Yoshino T, Shimizu Y, Honma T.

Inorg Chem. 2019 Aug 19;58(16):10890-10897. doi: 10.1021/acs.inorgchem.9b01273. Epub 2019 Aug 2.

PMID:
31373798
31.

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.

Kawahara T, Kojima T, Kandori S, Kurobe M, Yoshino T, Kimura T, Nagumo Y, Ishituka R, Mitsuzuka K, Narita S, Kobayashi T, Matsui Y, Ogawa O, Sugimoto M, Miyazaki J, Nishiyama H.

PLoS One. 2019 Aug 1;14(8):e0220173. doi: 10.1371/journal.pone.0220173. eCollection 2019.

32.

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer.

Nakamura Y, Sawada K, Fujii S, Yoshino T.

ESMO Open. 2019 Jul 8;4(3):e000530. doi: 10.1136/esmoopen-2019-000530. eCollection 2019. No abstract available.

33.

Classification of patients with cold sensation by a review of systems database: A single-centre observational study.

Yoshino T, Katayama K, Yamaguchi R, Imoto S, Miyano S, Mima H, Watanabe K.

Complement Ther Med. 2019 Aug;45:7-13. doi: 10.1016/j.ctim.2019.05.011. Epub 2019 May 11.

PMID:
31331585
34.

Prediction of deficiency-excess pattern in Japanese Kampo medicine: Multi-centre data collection.

Maeda-Minami A, Yoshino T, Katayama K, Horiba Y, Hikiami H, Shimada Y, Namiki T, Tahara E, Minamizawa K, Muramatsu S, Yamaguchi R, Imoto S, Miyano S, Mima H, Mimura M, Nakamura T, Watanabe K.

Complement Ther Med. 2019 Aug;45:228-233. doi: 10.1016/j.ctim.2019.07.003. Epub 2019 Jul 5.

PMID:
31331566
35.

Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.

Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O.

Clin Genitourin Cancer. 2019 Oct;17(5):e923-e929. doi: 10.1016/j.clgc.2019.04.017. Epub 2019 Jun 12.

PMID:
31307917
36.

Biological responses following one-stage full-mouth scaling and root planing with and without azithromycin: Multicenter randomized trial.

Yashima A, Morozumi T, Yoshie H, Hokari T, Izumi Y, Akizuki T, Mizutani K, Takamatsu H, Minabe M, Miyauchi S, Yoshino T, Tanaka M, Tanaka Y, Gomi K.

J Periodontal Res. 2019 Dec;54(6):709-719. doi: 10.1111/jre.12680. Epub 2019 Jul 10.

PMID:
31292965
37.

Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.

Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T.

Int J Clin Oncol. 2019 Jul 8. doi: 10.1007/s10147-019-01498-8. [Epub ahead of print]

PMID:
31286289
38.

Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis.

Iwamuro M, Tanaka T, Nishida K, Kanzaki H, Kawano S, Kawahara Y, Yoshino T, Okada H.

Ecancermedicalscience. 2019 Jun 3;13:933. doi: 10.3332/ecancer.2019.933. eCollection 2019.

39.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.

Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.

PMID:
31268130
40.

Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.

Yoshii A, Nagoshi T, Kashiwagi Y, Kimura H, Tanaka Y, Oi Y, Ito K, Yoshino T, Tanaka TD, Yoshimura M.

Cardiovasc Diabetol. 2019 Jul 1;18(1):85. doi: 10.1186/s12933-019-0889-y.

41.

A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects.

Ikeda T, Gion Y, Yoshino T, Sato Y.

J Clin Exp Hematop. 2019;59(2):64-71. doi: 10.3960/jslrt.18039.

42.

[A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].

Hattahara K, Yamasaki T, Sawada A, Tanigaki K, Endo S, Teramoto Y, Banno H, Fuchigami Y, Suzuki R, Fujiwara M, Hida T, Yoshino T, Kita Y, Goto T, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O.

Hinyokika Kiyo. 2019 May;65(5):157-161. doi: 10.14989/ActaUrolJap_65_5_157. Japanese.

PMID:
31247693
43.

[Retroperitoneal Dedifferentiated Liposarcoma with Metaplastic Bone Formation : A Case Report and Review of the Literature].

Yoshino T, Sejima C, Oka Y, Taniguchi H, Nagami T, Wake K, Yamamoto T, Ohnuma H, Kodama K, Kanazawa A, Kawakami K.

Hinyokika Kiyo. 2019 May;65(5):151-155. doi: 10.14989/ActaUrolJap_65_5_151. Review. Japanese.

PMID:
31247692
44.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum.

Int J Clin Oncol. 2019 Jun 15. doi: 10.1007/s10147-019-01485-z. [Epub ahead of print]

PMID:
31203527
45.

[Hyper-IL-6 syndrome mimicking IgG4-related disease].

Terao T, Yamamoto K, Ikeuchi K, Wakabayashi H, Igawa T, Inoue D, Oda W, Oyama T, Kamoi C, Sumii Y, Shiraishi Y, Yamamoto Y, Niiya D, Shiote Y, Sato Y, Yoshino T, Imajo K.

Rinsho Ketsueki. 2019;60(5):392-397. doi: 10.11406/rinketsu.60.392. Japanese.

PMID:
31168001
46.

Development and optimization of a high-throughput screening method utilizing Ancylostoma ceylanicum egg hatching to identify novel anthelmintics.

Abriola L, Hoyer D, Caffrey CR, Williams DL, Yoshino TP, Vermeire JJ.

PLoS One. 2019 Jun 3;14(6):e0217019. doi: 10.1371/journal.pone.0217019. eCollection 2019.

47.

Controlled isoflurane anesthesia exposure is required for reliable behavioral testing in murine surgical models.

Toyama K, Spin JM, Abe Y, Suzuki Y, Deng AC, Wagenhäuser MU, Yoshino T, Mulorz J, Liu S, Tsao PS, Mogi M.

J Pharmacol Sci. 2019 May;140(1):106-108. doi: 10.1016/j.jphs.2019.03.007. Epub 2019 May 11.

48.

Germ cell-less hybrid fish: ideal recipient for spermatogonial transplantation for the rapid production of donor-derived sperm†.

Xu D, Yoshino T, Konishi J, Yoshikawa H, Ino Y, Yazawa R, Dos Santos Nassif Lacerda SM, de França LR, Takeuchi Y.

Biol Reprod. 2019 Aug 1;101(2):492-500. doi: 10.1093/biolre/ioz045.

PMID:
31132090
49.

Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease.

Yoshida A, Kamata N, Yamada A, Yokoyama Y, Omori T, Fujii T, Hayashi R, Kinjo T, Matsui A, Fukata N, Takahashi S, Sakemi R, Ogata N, Ashizuka S, Bamba S, Ooi M, Kanmura S, Endo K, Yoshino T, Tanaka H, Morizane T, Shinzaki S, Kobayashi T.

Inflamm Intest Dis. 2019 Apr;3(4):167-172. doi: 10.1159/000495035. Epub 2019 Feb 6.

50.

Reply by Authors.

Fukunaga A, Kawaguchi T, Funada S, Yoshino T, Tabara Y, Matsuda F, Yoshimura K, Ogawa O, Negoro H; Nagahama Study Group.

J Urol. 2019 Aug;202(2):360-361. doi: 10.1097/01.JU.0000559826.09631.1d. Epub 2019 Jul 8. No abstract available.

PMID:
31095468

Supplemental Content

Loading ...
Support Center